Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: C31G vaginal gel; Glyminox gel; PRE 106; SAVVY

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosyn
  • Developer Biosyn; Louisiana State University Health Sciences Center; National Institute of Child Health and Human Development
  • Class Amines; Antibacterials; Antivirals; Small molecules; Spermicidal contraceptives; Unsaturated fatty acids
  • Mechanism of Action Membrane lipid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Pregnancy

Highest Development Phases

  • Suspended Pregnancy
  • No development reported Dendritic keratitis
  • Discontinued Chlamydial infections; Gonorrhoea; HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Dendritic-keratitis in USA (Ophthalmic)
  • 09 Sep 2013 Preclinical trials in Dendritic keratitis in USA (Ophthalmic)
  • 09 Sep 2013 Pharmacodynamics and adverse events data from preclinical studies in Dendritic keratitis released by Adamis Pharmaceuticals Corporation
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top